Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease
Aaron Broadwell, Arkadi Chines, Peter R Ebeling, Edward Franek, Shuang Huang, Shawna Smith, David Kendler, Osvaldo Messina, Paul D Miller, Aaron Broadwell, Arkadi Chines, Peter R Ebeling, Edward Franek, Shuang Huang, Shawna Smith, David Kendler, Osvaldo Messina, Paul D Miller
Abstract
Context: The effects of long-term exposure to denosumab in individuals with renal insufficiency are unknown.
Objective: This post hoc analysis evaluates the long-term safety and efficacy of denosumab in individuals with mild-to-moderate chronic kidney disease (CKD) (stages 2 and 3) using data from the pivotal phase 3, double-blind, 3-year FREEDOM (NCT00089791) and open-label, 7-year extension (NCT00523341) studies.
Participants and methods: Women age 60 to 90 years with a bone mineral density (BMD) T-score of less than -2.5 to greater than -4.0 at the total hip or lumbar spine were randomly assigned 1:1 to receive denosumab 60 mg subcutaneously every 6 months (long-term arm) or placebo (cross-over arm) in FREEDOM; eligible participants could enroll in the extension to receive denosumab 60 mg subcutaneously every 6 months. Change in estimated glomerular filtration rate (eGFR) from study baseline and annualized rates of fracture and adverse events (AEs) were the main outcome measures.
Results: Most participants (1259/1969 [64%] long-term arm; 1173/1781 [66%] crossover arm) with baseline CKD stage 2 or 3 remained within the same CKD subgroup at study completion; less than 3% progressed to CKD stage 4. Participants in all eGFR subgroups showed similar, persistent BMD gains over time and a low incidence of fractures. The percentage of participants reporting serious AEs was similar among renal subgroups (normal, CKD stage 2, CKD stage 3a, CKD stage 3b) both for the long-term (54% vs 52% vs 57% vs 58%) and crossover (43% vs 42% vs 43% vs 68%) arms, except CKD stage 3b subgroup, crossover arm.
Conclusion: The safety and efficacy of denosumab did not differ among participants with mild to moderate CKD.
Keywords: bone mineral density; chronic kidney disease; denosumab; fracture; safety.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
Figures
References
- Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19-28.
- Schaeffner ES, Ebert N, Delanaye P, et al. . Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157(7):471-481.
- Murphy D, McCulloch CE, Lin F, et al. ; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team . Trends in prevalence of chronic kidney disease in the United States. Ann Intern Med. 2016;165(7):473-481.
- Klawansky S, Komaroff E, Cavanaugh PF Jr, et al. . Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003;14(7):570-576.
- Dukas LC, Schacht E, Mazor Z, Stähelin HB. A new significant and independent risk factor for falls in elderly men and women: a low creatinine clearance of less than 65 ml/min. Osteoporos Int. 2005;16(3):332-338.
- Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone. 2006;38(2 Suppl 1):S4-S9.
- Roux C, Wyman A, Hooven FH, et al. ; GLOW investigators . Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int. 2012;23(12):2863-2871.
- Khairallah P, Nickolas TL. Management of osteoporosis in CKD. Clin J Am Soc Nephrol. 2018;13(6):962-969.
- Looker AC, Orwoll ES, Johnston CC Jr, et al. . Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12(11):1761-1768.
- Alem AM, Sherrard DJ, Gillen DL, et al. . Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58(1):396-399.
- Kim SM, Long J, Montez-Rath M, Leonard M, Chertow GM. Hip fracture in patients with non-dialysis-requiring chronic kidney disease. J Bone Miner Res. 2016;31(10):1803-1809.
- Yenchek RH, Ix JH, Shlipak MG, et al. ; Health, Aging, and Body Composition Study . Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol. 2012;7(7):1130-1136.
- Dukas L, Schacht E, Stähelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of < 65 ml/min is a risk factor for falls and fractures. Osteoporos Int. 2005;16(12):1683-1690.
- Ensrud KE, Lui LY, Taylor BC, et al. ; Osteoporotic Fractures Research Group . Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med. 2007;167(2):133-139.
- Fried LF, Biggs ML, Shlipak MG, et al. . Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18(1):282-286.
- Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-3232.
- Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication safety principles and practice in CKD. Clin J Am Soc Nephrol. 2018;13(11):1738-1746.
- Cummings SR, San Martin J, McClung MR, et al. ; FREEDOM Trial . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
- Jamal SA, Ljunggren O, Stehman-Breen C, et al. . Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011;26(8):1829-1835.
- Bone HG, Wagman RB, Brandi ML, et al. . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513-523.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011). 2017;7(1):1-59.
- Goldenstein PT, Jamal SA, Moysés RM. Fractures in chronic kidney disease: pursuing the best screening and management. Curr Opin Nephrol Hypertens. 2015;24(4):317-323.
- Miller PD. The role of bone biopsy in patients with chronic renal failure. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S140-S150.
- Miller PD. Fragility fractures in chronic kidney disease: an opinion-based approach. Cleve Clin J Med. 2009;76(12):715-723.
- Jamal SA, Bauer DC, Ensrud KE, et al. . Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J Bone Miner Res. 2007;22(4):503-508.
- Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105-2115.
- Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010;56(1):57-68.
- Chesnut CH III, Skag A, Christiansen C, et al. ; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-1249.
- Eisman JA, Civitelli R, Adami S, et al. . Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008;35(3):488-497.
- Miller PD, Jamal SA, Evenepoel P, Eastell R, Boonen S. Renal safety in patients treated with bisphosphonates for osteoporosis: a review. J Bone Miner Res. 2013;28(10):2049-2059.
- Brown JP, Prince RL, Deal C, et al. . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161.
- Lyu H, Jundi B, Xu C, et al. . Comparison of denosumab and bisphosphonates in patients with osteoporosis: a meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2019;104(5):1753-1765.
- Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471-1479.
- Cummings SR, Ferrari S, Eastell R, et al. . Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190-198.
- Dusso AS. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney Int Suppl (2011). 2011;1(4):136-141.
- Huynh AL, Baker ST, Stewardson AJ, Johnson DF. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Pharmacoepidemiol Drug Saf. 2016;25(11):1274-1278.
- Dave V, Chiang CY, Booth J, Mount PF. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Am J Nephrol. 2015;41(2):129-137.
- Jalleh R, Basu G, Le Leu R, Jesudason S. Denosumab-induced severe hypocalcaemia in chronic kidney disease. Case Rep Nephrol. 2018;2018:7384763.
- Festuccia F, Jafari MT, Moioli A, et al. . Safety and efficacy of denosumab in osteoporotic hemodialysed patients. J Nephrol. 2017;30(2):271-279.
Source: PubMed